KALARIS THERAPEUTICS, INC. Operating Expenses
KALARIS THERAPEUTICS, INC. (KLRS) reported Operating Expenses of $12.39 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-11
- KALARIS THERAPEUTICS, INC. operating expenses for the quarter ending 2026-06-30 was $12.39M, a 1.06% increase year-over-year.
- KALARIS THERAPEUTICS, INC. operating expenses for the quarter ending 2026-03-31 was $11.83M, a 14.28% increase year-over-year.
- KALARIS THERAPEUTICS, INC. operating expenses for the quarter ending 2025-12-31 was $10.80M, a 51.42% increase year-over-year.
- KALARIS THERAPEUTICS, INC. operating expenses for the quarter ending 2025-09-30 was $12.74M, a 66.34% decline year-over-year.
- KALARIS THERAPEUTICS, INC. operating expenses for fiscal 2025 was $46.15M, a 10.79% decline from fiscal 2024.
- KALARIS THERAPEUTICS, INC. operating expenses for fiscal 2024 was $51.73M, a 74.12% decline from fiscal 2023.
- KALARIS THERAPEUTICS, INC. operating expenses for fiscal 2023 was $199.90M, a 16.76% increase from fiscal 2022.
- KALARIS THERAPEUTICS, INC. operating expenses for fiscal 2022 was $171.20M, a 0.81% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 3 month as first filed | Operating Expenses 6 month | Operating Expenses 6 month as first filed | Operating Expenses 9 month | Operating Expenses 12 month | Operating Expenses 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $12.39M 10-Q · filed 2026-08-11 | $24.22M 10-Q · filed 2026-08-11 | $35.02M derived: sum of 3 quarters · filed 2026-08-11 | $47.76M derived: sum of 4 quarters · filed 2026-08-11 | |||
| 2026-03-31 | $11.83M 10-Q · filed 2026-05-12 | $22.63M derived: sum of 2 quarters · filed 2026-05-12 | $35.38M derived: sum of 3 quarters · filed 2026-05-12 | $47.63M derived: sum of 4 quarters · filed 2026-08-11 | |||
| 2025-12-31 | $10.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $23.54M derived: sum of 2 quarters · filed 2026-03-17 | $35.80M derived: sum of 3 quarters · filed 2026-08-11 | $46.15M 10-K · filed 2026-03-17 | |||
| 2025-09-30 | $12.74M 10-Q · filed 2025-11-12 | $25.00M derived: sum of 2 quarters · filed 2026-08-11 | $35.35M 10-Q · filed 2025-11-12 | $42.48M derived: sum of 4 quarters · filed 2026-08-11 | |||
| 2025-06-30 | $12.26M 10-Q · filed 2026-08-11 | $22.61M 10-Q · filed 2026-08-11 | $29.74M derived: sum of 3 quarters · filed 2026-08-11 | $67.59M derived: sum of 4 quarters · filed 2026-08-11 | |||
| 2025-03-31 | $10.35M 10-Q · filed 2026-05-12 | $17.49M derived: sum of 2 quarters · filed 2026-05-12 | $55.34M derived: sum of 3 quarters · filed 2026-05-12 | $59.52M derived: sum of 4 quarters · filed 2026-05-12 | |||
| 2024-12-31 | $7.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $44.98M derived: sum of 2 quarters · filed 2026-03-17 | $49.17M derived: sum of 3 quarters · filed 2026-03-17 | $51.73M 10-K · filed 2026-03-17 | $65.44M 10-K · filed 2025-03-07 | ||
| 2024-09-30 | $37.85M 10-Q · filed 2025-11-12 | $42.04M derived: sum of 2 quarters · filed 2025-11-12 | $44.60M 10-Q · filed 2025-11-12 | $107.00M derived: sum of 4 quarters · filed 2025-11-12 | |||
| 2024-06-30 | $4.19M 10-Q · filed 2025-08-13 | $7.77M 10-Q · filed 2024-08-09 | $6.75M 10-Q · filed 2025-08-13 | $40.07M 10-Q · filed 2024-08-09 | $69.16M derived: sum of 3 quarters · filed 2025-08-13 | $116.12M derived: sum of 4 quarters · filed 2025-08-13 | |
| 2024-03-31 | $2.56M 10-Q · filed 2025-05-14 | $32.30M 10-Q · filed 2024-05-13 | $64.97M derived: sum of 2 quarters · filed 2025-05-14 | $111.93M derived: sum of 3 quarters · filed 2025-05-14 | $159.23M derived: sum of 4 quarters · filed 2025-05-14 | ||
| 2023-12-31 | $62.41M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-07 | $109.37M derived: sum of 2 quarters · filed 2025-03-07 | $156.67M derived: sum of 3 quarters · filed 2025-03-07 | $199.90M 10-K · filed 2025-03-07 | |||
| 2023-09-30 | $46.96M 10-Q · filed 2023-11-02 | $94.27M derived: sum of 2 quarters · filed 2024-08-09 | $137.50M 10-Q · filed 2023-11-02 | $177.93M derived: sum of 4 quarters · filed 2024-08-09 | |||
| 2023-06-30 | $47.30M 10-Q · filed 2024-08-09 | $90.53M 10-Q · filed 2024-08-09 | $130.97M derived: sum of 3 quarters · filed 2024-08-09 | $173.92M derived: sum of 4 quarters · filed 2024-08-09 | |||
| 2023-03-31 | $43.23M 10-Q · filed 2024-05-13 | $83.67M derived: sum of 2 quarters · filed 2024-05-13 | $126.61M derived: sum of 3 quarters · filed 2024-05-13 | $171.24M derived: sum of 4 quarters · filed 2024-05-13 | |||
| 2022-12-31 | $40.43M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | $83.38M derived: sum of 2 quarters · filed 2024-03-15 | $128.01M derived: sum of 3 quarters · filed 2024-03-15 | $171.20M 10-K · filed 2024-03-15 | |||
| 2022-09-30 | $42.95M 10-Q · filed 2023-11-02 | $87.57M derived: sum of 2 quarters · filed 2023-11-02 | $130.77M 10-Q · filed 2023-11-02 | $186.56M derived: sum of 4 quarters · filed 2023-11-02 | |||
| 2022-06-30 | $44.62M 10-Q · filed 2023-08-03 | $87.82M 10-Q · filed 2023-08-03 | $143.61M derived: sum of 3 quarters · filed 2023-08-03 | $189.12M derived: sum of 4 quarters · filed 2023-08-03 | |||
| 2022-03-31 | $43.19M 10-Q · filed 2023-05-04 | $98.99M derived: sum of 2 quarters · filed 2023-05-04 | $144.49M derived: sum of 3 quarters · filed 2023-05-04 | $182.15M derived: sum of 4 quarters · filed 2023-05-04 | |||
| 2021-12-31 | $55.80M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-15 | $101.30M derived: sum of 2 quarters · filed 2023-02-15 | $138.96M derived: sum of 3 quarters · filed 2023-02-15 | $169.82M 10-K · filed 2023-02-15 | |||
| 2021-09-30 | $45.50M 10-Q · filed 2022-11-03 | $83.16M derived: sum of 2 quarters · filed 2022-11-03 | $114.02M 10-Q · filed 2022-11-03 | $139.44M derived: sum of 4 quarters · filed 2022-11-03 | |||
| 2021-06-30 | $37.66M 10-Q · filed 2022-08-04 | $68.52M 10-Q · filed 2022-08-04 | $93.93M derived: sum of 3 quarters · filed 2022-08-04 | $117.83M derived: sum of 4 quarters · filed 2022-08-04 | |||
| 2021-03-31 | $30.86M 10-Q · filed 2022-05-05 | $56.28M derived: sum of 2 quarters · filed 2022-05-05 | $80.18M derived: sum of 3 quarters · filed 2022-05-05 | $92.33M derived: sum of 4 quarters · filed 2022-05-05 | |||
| 2020-12-31 | $25.42M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-10 | $49.32M derived: sum of 2 quarters · filed 2022-02-10 | $61.47M derived: sum of 3 quarters · filed 2022-02-10 | $71.31M 10-K · filed 2022-02-10 | |||
| 2020-09-30 | $23.90M 10-Q · filed 2021-11-05 | $36.05M derived: sum of 2 quarters · filed 2021-11-05 | $45.89M 10-Q · filed 2021-11-05 | $55.40M derived: sum of 4 quarters · filed 2021-11-05 | |||
| 2020-06-30 | $12.15M 10-Q · filed 2021-08-06 | $21.99M 10-Q · filed 2021-08-06 | $31.50M derived: sum of 3 quarters · filed 2021-08-06 | $39.98M derived: sum of 4 quarters · filed 2021-08-06 | |||
| 2020-03-31 | $9.84M 10-Q · filed 2021-05-06 | $19.34M derived: sum of 2 quarters · filed 2021-05-06 | $27.82M derived: sum of 3 quarters · filed 2021-05-06 | $33.77M derived: sum of 4 quarters · filed 2021-05-06 | |||
| 2019-12-31 | $9.51M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-12 | $17.98M derived: sum of 2 quarters · filed 2021-02-12 | $23.93M derived: sum of 3 quarters · filed 2021-02-12 | $26.87M 10-K · filed 2021-02-12 | |||
| 2019-09-30 | $8.48M 10-Q · filed 2020-11-10 | $14.42M derived: sum of 2 quarters · filed 2020-11-10 | $17.36M 10-Q · filed 2020-11-10 | ||||
| 2019-06-30 | $5.95M 10-Q · filed 2020-09-02 | $8.88M 10-Q · filed 2020-09-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |